Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Glaukos Corporation (GKOS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret the information. Glaukos is an ophthalmic pharmaceutical and medical technology company focused on therapies for glaucoma, corneal disorders, and retinal diseases, and its filings provide detailed insight into this business.
Through periodic reports such as Forms 10-Q and 10-K, investors can review Glaukos’ net sales, segment performance in glaucoma and corneal health, gross margins, operating expenses, and net income or loss. These filings also describe risk factors relevant to its ophthalmic device and pharmaceutical portfolio, including regulatory requirements, clinical trial processes, reimbursement dynamics, manufacturing considerations, and intellectual property matters referenced in the company’s public communications.
Current reports on Form 8-K capture material events such as quarterly and annual financial results, preliminary net sales updates, and investor presentations. For example, Glaukos has filed 8-Ks to furnish press releases on second and third quarter financial results, preliminary unaudited net sales for a fiscal year, and investor presentation materials. These documents often include or reference revenue guidance ranges and explanations of non-GAAP financial measures and constant currency net sales metrics.
On Stock Titan, AI-generated summaries help explain the key points of lengthy filings, highlighting items such as revenue trends, segment details, and notable risk disclosures without replacing the full text. Real-time updates from EDGAR ensure new Glaukos filings appear promptly, while dedicated sections make it straightforward to locate quarterly reports, annual reports, and current reports tied to material announcements.
For users analyzing GKOS, this page offers a structured view of Glaukos’ SEC reporting history alongside AI insights that clarify complex financial and regulatory information related to its ophthalmic pharmaceutical and medical technology activities.
Joseph E. Gilliam, President & COO of Glaukos Corporation (GKOS), reported a Form 4 transaction dated 09/18/2025. The filing shows 3,884 shares of common stock were acquired at no cash cost as the result of portion of a 2021 restricted stock unit award becoming earned after the company determined two operational targets were achieved. After the transaction, Mr. Gilliam beneficially owns 112,762 shares, which includes 64,547 restricted stock units still unvested and 167 shares purchased via the ESPP. Half of the newly earned shares will vest and be delivered on 09/23/2025 and the remainder in June 2026. The Form 4 was filed as an individual report.
Thomas W. Burns, Chairman & CEO of Glaukos Corporation (GKOS), reported Form 4 transactions. The filing shows vesting and delivery of restricted stock units after the board committee determined two operational performance targets were achieved. On 09/18/2025, 15,417 shares underlying a 2021 performance RSU award were deemed earned (50% to vest on 09/23/2025; remaining 50% in June 2026). A sale of 1,098 shares occurred on 09/19/2025 at $83.47 per share. The report lists substantial indirect holdings through several family and trust vehicles totaling 1,452,039 shares across named trusts and RSUs that remain unvested.
Form 144 notice for Glaukos Corp (GKOS) reports a proposed sale of 517 restricted common shares by a person whose securities vested on 09/19/2024 and were acquired as compensation. The broker listed is Fidelity Brokerage Services LLC and the aggregate market value of the proposed sale is $43,541.07 with an approximate sale date of 09/22/2025 on the NYSE. The filing also discloses that the same person sold 5,142 common shares on 09/11/2025 for gross proceeds of $453,607.98. The notice includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.
Glaukos Corp (GKOS) insider sale by Chief Development Officer. The filing shows Tomas Navratil sold a total of 5,142 shares on 09/11/2025 under a Rule 10b5-1 trading plan adopted June 12, 2025, at weighted average prices of $87.98 and $88.61. Following these transactions the reporting person beneficially owned 75,469 shares, which include 42,589 restricted stock units that have not vested or been delivered. The filing discloses the sales were executed in multiple trades with price ranges of $87.43–$88.43 and $88.44–$88.88 and states the reporter will provide full trade-by-trade details upon request.
Glaukos Corporation (GKOS) filed a Form 144 reporting a proposed sale of 5,142 common shares, acquired through restricted stock vesting as compensation during March–July 2024. The filing lists an aggregate market value of $453,607.98 for the shares and reports 57,349,987 shares outstanding. The proposed sale date is 09/11/2025 and the broker is listed as Fidelity Brokerage Services LLC on the NYSE. The filer reports no securities sold during the past three months and attests not to possess undisclosed material information.
Glaukos Corporation filed a Form S-8 registration statement to register additional shares of its common stock for issuance under the Glaukos Corporation 2015 Employee Stock Purchase Plan. This filing uses the abbreviated process under General Instruction E to Form S-8, meaning it builds on earlier registration statements for the same plan.
The company incorporates by reference its previously filed Exchange Act reports, so future SEC filings will automatically update this registration. An opinion on the validity of the common stock being registered is provided by Robert Davis, the company’s Senior Vice President, General Counsel and Business Development. The document also includes standard consents, an exhibit index for the ESPP, and signatures from the CEO, CFO, and all directors authorizing the filing.
Wellington Management reports beneficial ownership of 3,244,404 shares of Glaukos Corporation common stock, representing approximately 5.68% of the class. The filing shows no sole voting or dispositive power; voting power is shared for about 2,833,990 shares while shared dispositive power equals the full 3,244,404 shares disclosed.
The securities are owned of record by clients of Wellington investment advisers and are reported as held in the ordinary course of business on a Schedule 13G. Multiple Wellington entities are listed as reporting persons and two classifications appear: several entities as HC (holding companies) and Wellington Management Company LLP as IA (investment adviser).
Glaukos Corporation disclosed that it will present an investor presentation attached as Exhibit 99.1 to this Current Report and that the presentation will be made available on the company’s investor website. The company states the presentation may be used in investor and stakeholder meetings and that the information in Item 7.01 and Exhibit 99.1 is not intended to be deemed filed under the Exchange Act or incorporated by reference in other filings unless explicitly stated.
The report also lists an interactive cover page data file as Exhibit 104. No financial statements, earnings data, or material transactions are included in this filing.